Fresh analysis indicates that people who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who stop conventional diet and exercise regimens.
Research printed in a leading health publication points out that while obese people can lose about a fifth of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month once they quit.
"People using these medications need to be informed of the potential of fast weight regain when the treatment ends," stated lead investigator Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment weight in about 18 months.
Comparing Treatments
The study, which examined 37 of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods.
Researchers emphasize that people who lose weight through dieting generally have a slower weight regain—perhaps 100 grams monthly—after stopping.
Explaining the Rapid Rebound
Experts believe the mechanism of the drugs accounts for the accelerated regain.
These medications imitate a natural hormone called GLP-1, which moderates hunger.
"Artificially providing the hormone levels far above than normal could lead to the system to generate a reduced amount of its own natural GLP-1, and could reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Stopping of this medication results in appetite is unsuppressed, making overeating much more probable."
An Ongoing Issue?
Health authorities advise the jabs for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Professionals say that, considering the high risk of relapse, the therapy is often ongoing.
This view is reinforced by pharmaceutical companies, who note that the findings "emphasize the persistent character of excess weight," similar to managing diseases like high blood pressure.
Patient Experiences
Users who have come off the medication describe a intense return of cravings.
"I experienced a switch flipping and I was suddenly ravenous," said an individual.
The struggle is exacerbated if users have not adopted permanent dietary or behavioural modifications during treatment.
Widespread Adoption
Survey data indicate that a significant number of people in the UK have used weight-loss jabs in the past year, with demand remaining high.
- Use is higher among females compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, researchers caution that while these medications are effective agents for weight loss, they are not a permanent fix and maintained weight loss hinges on combined behavioural support.
